The world-renowned pharmaceutical company, Roche, not only manufactures drugs but has recently begun marketing digital diagnostics for faster and more accurate image analysis of breast cancer. The „Roche uPath Enterprise Digital Pathology Software“ uses two algorithms to detect breast cancer tissue through the process of machine learning. In this way, physicians and pathologists can distinguish abnormal tissue areas from normal tissue areas. Part of this digital diagnostic solution can also be used to better and more quickly diagnose lung cancer, specifically lung cancer of the non-small cell type. Parts of this image recognition software have already been on the market since June 2020. Roche’s competitor, the Philips company, has already presented similar pioneer diagnostic solutions to the public in 2019, according to the trade magazine „Medtechdive.com“. However, competitors in this market also include the pharmaceutical company Novartis, which has developed a so-called AI laboratory in cooperation with Microsoft, which works out cell and gene therapies according to machine learning methods.
Source: Netzwoche